Advanced diagnostics and prediction of therapeutic efficacy for humans
We offer an innovative technology for tumor diagnostics and prediction of treatment effectiveness, based on patient-friendly fine needle biopsies
We build on the latest developments in genetics and protein analysis of tumors, and provides more accurate diagnoses and predictions about which therapy to use in individual cases
We use AI-based tools for these purposes. This technology will accelerate tumor diagnostics and improve health economics.
How could we transform and improve cancer diagnostics in a world with rising numbers of cancer patients?
Addressing the Rising Demand for Cancer Diagnostics
The global increase in cancer cases is creating an urgent need for safer, more efficient, and scalable diagnostic solutions. To ensure every patient receives the best possible therapy, healthcare systems must adopt cost-effective methods that close gaps in patient care.
The Limitations of Current Biopsy Methods
Traditional Core Needle Biopsy (CNB) remains the standard for diagnosing solid tumors. However, CNB is invasive, carries risks of complications, and can be difficult to repeat—making it less suitable for ongoing treatment monitoring.
Minimally invasive sampling
Such as liquid biopsies and fine needle approaches, reduce patient risk and discomfort.
Unlocking the Next Competitive Edge: AI-Driven Diagnostics
Artificial intelligence (AI) is transforming cancer diagnostics by enabling:
Continuous monitoring: Scalable AI solutions allow for repeatable, real-time assessment of treatment effectiveness.
Personalized care: Advanced algorithms help identify the most effective therapies for each patient, closing care gaps and improving outcomes.
What we offer to improve research development, treatment decisions and precision medicine
Precision Biopsies combines cutting-edge science with a scalable business model, targeting a high-growth market with clear unmet needs. We invite investors to join us as we accelerate commercialization and establish leadership in precision oncology diagnostics
Potential customers include private healthcare providers, pharmaceutical companies, and certain public healthcare institutions.
We offer analyses ranging from early diagnostics to longitudinal follow-up, where the use of fine needle biopsy has major advantages due to its non-invasive nature, low risk of complications, and comprehensive information for precision cancer therapy. In addition to its role in direct cancer care and in relation to drug treatment, it provides pharmaceutical companies with the opportunity to evaluate their drugs earlier.
Partner With Us
We are redefining precision oncology through minimally invasive sampling, multi-omics, and AI-powered insights. Join us to advance innovation, improve outcomes, and unlock growth in a rapidly expanding healthcare market.
Precision Biopsies is in an early stage with a very high level of scientific excellence from a clinical perspective and significant international market potential. Favorable competitive position internationally.
The company is at the forefront of this new technology
The Institute for Health Economics (IHE) is currently investigating the health economic benefits of our technology.